about
X-linked sex-determining region Y box 3 (SOX3) gene mutations are uncommon in men with idiopathic oligoazoospermic infertilityNuclear receptors Sf1 and Dax1 function cooperatively to mediate somatic cell differentiation during testis development[Endoscopy versus microsurgery: results in a consecutive series of nonfunctioning pituitary adenomas].Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up.Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1.Hypothalamo-pituitary sarcoidosis: a multicenter study of 24 patients.Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans.Non-functioning pituitary macro-incidentalomas benefit from early surgery before becoming symptomatic.Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature.Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.Giant prolactinomas in women.Silent GH pituitary tumor: diagnostic and therapeutic challenges.Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.A prognostic clinicopathologic classification of pituitary endocrine tumors.Biological and radiological exploration and management of non-functioning pituitary adenoma.Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification.Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas.HMGA1-pseudogene expression is induced in human pituitary tumors.Mir-23b and miR-130b expression is downregulated in pituitary adenomas.Silent somatotroph tumour revisited from a study of 80 patients with and without acromegaly and a review of the literature.Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences.MicroRNAs in pituitary tumors.New targeted therapies in pituitary carcinoma resistant to temozolomide.Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth.Macroprolactinomas in children and adolescents: factors associated with the response to treatment in 77 patients.Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study.Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.Cabergoline therapy of paraneoplastic Cushing syndrome in children.Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.18F-FDG PET/CT findings in a patient with isolated intracranial Rosai-Dorfman disease.Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors.Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women.From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal.T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.Predicting visual outcome after treatment of pituitary adenomas with optical coherence tomography.A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up.Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma.Proliferation markers of human pituitary tumors: contribution of a genome-wide transcriptome approach.European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.
P50
Q28275520-DB576916-EC51-4B91-83A4-46A90F3568CEQ28510433-01D1894B-9AE8-41E6-8D4C-447EE8B2A727Q33500457-F6509537-BE25-4FAA-8860-DCF3DF57FE32Q33531990-1E2419EC-7699-4425-8874-E89F13A324D0Q34273288-9C31A789-25DA-45FE-9D4F-4DE91EDE95E8Q34323918-EDE4108D-55BC-49C4-8323-CEC2428753E4Q34565828-D8BB369D-A64B-4204-ADAE-719082D3291AQ35049918-18BE6F7C-AB0C-4273-A65C-B402A9623E34Q36152127-B1AAF1ED-98DA-4F20-B789-3F16A0DDB8C9Q37992191-34E4E3CE-E1BB-41C9-8622-7C9F09EF0D5DQ38148633-84507383-7F5B-4FB0-A4A2-9B42E793D07EQ38164979-102BFD78-388D-44A7-99E2-B860FE2D2E8BQ38178912-B30DE7A8-4848-41F8-923F-BFEE0F30F991Q38366903-2734AA4B-E084-478C-8717-5D4ED43EF3ECQ38540037-1D59EE3C-2B49-4C21-A6F6-D913F8AE83B7Q38666518-DB6ECBAC-3E97-4476-87F6-5BC45628D95AQ38825813-36F23BC0-0EF9-40B9-8FC4-201DA8956C44Q38848871-1FF3429D-C736-44FC-84F1-571B900AB3F5Q38884465-011B6F74-5894-434D-9E53-DE3D46C5431EQ39010323-60649AEB-C96A-4625-B81F-0714DFEB5B58Q39027942-7B524052-BF2E-48A8-AE7A-B10992A7AF3EQ39065001-C0732620-67BE-4026-90A6-113C9A92BC00Q39089675-BDCBEB03-9E90-4050-A6CF-A817AEC29277Q39715502-43F68234-EDE9-428C-AE48-6C64E29145F3Q41190054-48D8E118-2F43-4E39-872C-749756FFFABFQ41659209-77ECEAA9-B13D-40C4-BEE9-6C3FA89B7193Q42946254-7C11631A-26E2-4409-A70C-84EAA0F6EABEQ42957576-01BE0CD1-061C-4770-9D44-850CE38F5546Q42958207-22FC88D2-0389-49D5-A505-9511FC76C151Q43102415-897ED112-F5C8-4E43-9236-F9E67D5922CEQ43742627-B6832968-FFAC-46A5-9D6E-7A29C2AB73B3Q44588158-897B7E20-C07A-4354-93D9-5DBC59637E6CQ44757183-E86AA938-A334-409A-A1F3-ADC796582A4AQ45054086-890ABC77-2D94-4CC0-BE7C-608D03D07D8CQ46278802-2525FB0C-887F-42F0-A5B3-FD1D9DE1B868Q46386804-8DE3B4D0-9732-45BF-A377-42C6762801A2Q46411571-6895823F-0B4F-4498-A6B6-02912F3E5A38Q46450213-1185DDB1-2EEC-4708-A573-2224A3B31FCCQ46517416-FDFFCBB7-1B87-4992-ACB5-260C7B081647Q46894881-6C195970-DA84-4DA1-AD63-8D655A3724AF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gérald Raverot
@ast
Gérald Raverot
@en
Gérald Raverot
@es
Gérald Raverot
@nl
Gérald Raverot
@sl
type
label
Gérald Raverot
@ast
Gérald Raverot
@en
Gérald Raverot
@es
Gérald Raverot
@nl
Gérald Raverot
@sl
prefLabel
Gérald Raverot
@ast
Gérald Raverot
@en
Gérald Raverot
@es
Gérald Raverot
@nl
Gérald Raverot
@sl
P1053
C-3859-2013
P106
P1153
7801436241
P21
P31
P3829
P3835
gerald-raverot
P496
0000-0002-9517-338X